Suscribirse

Chronic ozone exposure in mice mimics clinical asthma-COPD overlap syndrome and is attenuated by tiotropium - 20/03/24

Doi : 10.1016/j.rmr.2024.01.027 
P. Chenuet 1, S. Huot-Marchant 2, , A. Ledru 1, L. Fauconnier 1, M. Mellier 1, N. Rouxel 1, L. Allimonnier 1, C. Serdjebi 3, Y. Julé 3, N. Riteau 2, I. Couillin 2, D. Togbé 2, V. Quesniaux 2, B. Ryffel 2, N. Segueni 1
1 ArtImmune SAS, 13, avenue Buffon, Orleans, France 
2 Experimental molecular immunology and neurogenetics (INEM), UMR 7355 CNRS-university of Orleans, 45071 Orleans cedex 2, France 
3 Biocellvia, Marseille, France 

Corresponding author.

Resumen

Environmental air pollutants including ozone cause severe irritation and respiratory diseases. Here, we report that 6week's ozone exposure in mice (1.5ppm, twice weekly) causes airway hyperreactivity, eosinophil and neutrophil recruitment, Th2 immune response, respiratory barrier disruption with inflammation, fibrosis and emphysema reminiscent of COPD, more rapidly than cigarette smoke exposure. This model features important aspects of asthma-COPD overlap syndrome (ACOS) as recently described in patients. Since Tiotropium (TTP), an anticholinergic receptor antagonist, blocks smooth muscle cell contraction and mucus secretion with a prolonged bronchodilator effect in patients with asthma or COPD, we asked whether its effect is limited to bronchodilation. We report here that Tiotropium not only reduced airways hyperreactivity, but also drastically diminished eosinophil recruitment, Th2 cell response and ozone-induced lung inflammatory pathology including emphysema. Therefore, chronic O3-induced lung pathology in mice mimics ACOS in patients and is attenuated by TTP treatment. The mechanisms of TTP protective effect on respiratory barrier disruption and chronic inflammation need to be further explored.

El texto completo de este artículo está disponible en PDF.

Keywords : Ozone, ACOS, Tiotropium, Airway hyperreactivity, Lung emphysema, Eosinophilia


Esquema


© 2024  Publicado por Elsevier Masson SAS.
Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 41 - N° 3

P. 193-194 - mars 2024 Regresar al número
Artículo precedente Artículo precedente
  • Bénéfices de la réparation épithéliale bronchique par les iPSC dans la BPCO
  • M. Nadaud, C. Bourdais, A. Fort-Petit, J. De Vos, K. Hireche, I. Vachier, E. Ahmed, A. Bourdin
| Artículo siguiente Artículo siguiente
  • Dysfunction of AT2–AT1 transition in emphysema
  • M. Toigo, B. Ribeiro Baptista, G. Justeau, J. Boczkowski, J. Gote-Schniering, L. Boyer

¿Ya suscrito a @@106933@@ revista ?